Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its hum… Read more
Avecho Biotechnology Limited (AVEFF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 5.492x
Based on the latest financial reports, Avecho Biotechnology Limited (AVEFF) has a cash flow conversion efficiency ratio of 5.492x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.53 Million) by net assets ($825.16K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Avecho Biotechnology Limited - Cash Flow Conversion Efficiency Trend (2013–2023)
This chart illustrates how Avecho Biotechnology Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Avecho Biotechnology Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avecho Biotechnology Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zena Mining Corp
V:ZCC-H
|
-0.017x |
|
Transatlantic Mining Corp
PINK:TRRGF
|
8.451x |
|
Gateway Real Estate AG
XETRA:GTY
|
-0.048x |
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
0.070x |
|
IT Tech Packaging Inc
NYSE MKT:ITP
|
0.010x |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
-0.007x |
|
AlphaTON Capital Corp.
NASDAQ:ATON
|
-0.080x |
|
Investsmart Group Ltd
AU:INV
|
0.282x |
Annual Cash Flow Conversion Efficiency for Avecho Biotechnology Limited (2013–2023)
The table below shows the annual cash flow conversion efficiency of Avecho Biotechnology Limited from 2013 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $6.38 Million | $-3.18 Million | -0.499x | +27.39% |
| 2022-12-31 | $2.42 Million | $-1.67 Million | -0.687x | -0.54% |
| 2021-12-31 | $4.54 Million | $-3.10 Million | -0.683x | -27.40% |
| 2020-12-31 | $2.65 Million | $-1.42 Million | -0.536x | -314.63% |
| 2019-12-31 | $4.76 Million | $1.19 Million | 0.250x | +145.41% |
| 2018-12-31 | $3.90 Million | $-2.15 Million | -0.550x | +44.85% |
| 2017-12-31 | $6.40 Million | $-6.39 Million | -0.997x | -86.15% |
| 2016-12-31 | $11.65 Million | $-6.24 Million | -0.536x | -89.15% |
| 2015-12-31 | $28.93 Million | $-8.20 Million | -0.283x | -106.10% |
| 2014-12-31 | $49.03 Million | $-6.74 Million | -0.137x | +34.67% |
| 2013-12-31 | $40.77 Million | $-8.58 Million | -0.210x | -- |